Target Name: MIR454
NCBI ID: G768216
Review Report on MIR454 Target / Biomarker Content of Review Report on MIR454 Target / Biomarker
MIR454
Other Name(s): mir-454 | MIRN454 | hsa-miR-454-3p | microRNA 454 | hsa-miR-454-5p | hsa-mir-454 | MicroRNA 454

MIR454: A Potential Drug Target and Biomarker

MIR454, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and functional make it an attractive target for drug development due to its ability to regulate cell proliferation and survival . In this article, we will explore the biology of MIR454, its potential as a drug target, and its potential as a biomarker for various diseases.

MIR454: A Non-Code RNA Molecule

MIR454 is a non-coding RNA molecule that was first identified in the gene library of the National Library of China. It has a length of 218 nucleotides and an average width of 64 nucleotides. MIR454 is expressed in various tissues and cells in the body, including the brain, heart, liver, and cancer cells.

MIR454's Unique Structure and Functional Domains

MIR454 has a unique structure that consists of three distinct domains: a 5' non-coding region, a 3' non-coding region, and a 2'-cDNA-binding domain. The 5' non-coding region contains three overlapping UTRs (uracil nucleotide triphosphate) and a potential RNA-binding domain. The 3' non-coding region contains a stem-loop structure that is similar to that of the TATA (TATA-binding) RNA element , a regulatory element that is found in various gene promoters. The 2'-cDNA-binding domain is responsible for binding to the cDNA of the gene.

MIR454's Functions

MIR454 has been shown to play a role in various cellular processes, including cell proliferation, apoptosis, and inflammation. Studies have shown that MIR454 can promote cell proliferation by regulating the G1/S transition and cell cycle progression. Additionally , MIR454 has been shown to induce cell apoptosis, which is a natural response to various stimuli, including exposure to chemotherapy drugs.

MIR454's Potential as a Drug Target

MIR454's unique structure and functional domains make it an attractive target for drug development due to its ability to regulate cell proliferation and survival. Several studies have shown that MIR454 can be inhibited by small molecules, including inhibitors of the PI3K/Akt signaling pathway. Additionally, MIR454 has been shown to interact with several protein kinases, including the mitochondrial protein p62. This suggests that MIR454 may be a useful target for inhibiting cell proliferation and survival in various diseases.

MIR454's Potential as a Biomarker

MIR454 has also been shown to be a potential biomarker for several diseases, including cancer. Its unique structure and functional domains make it an attractive target for diagnostic assays, including qRT-PCR, RNA-seq, and mass spectrometry. Several studies have shown that MIR454 can be used as a biomarker for various types of cancer, including breast, lung, and colorectal cancers.

Conclusion

MIR454 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and functional domains make it an attractive target for drug development, and its potential as a biomarker for various types of cancer makes it an promising tool for diagnostic assays. Further research is needed to fully understand the biology of MIR454 and its potential as a drug and biomarker.

Protein Name: MicroRNA 454

The "MIR454 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR454 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708 | MIR4709 | MIR4711 | MIR4712 | MIR4713 | MIR4713HG | MIR4714 | MIR4715 | MIR4716 | MIR4717 | MIR4718 | MIR4720 | MIR4721 | MIR4722 | MIR4723 | MIR4724 | MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734